Malarial vaccine based on an adenoviral vector containing a B cell epitope

2010 Science-Business eXchange  
Approach Summary Licensing status Publication and contact information Drug delivery Malarial vaccine based on an adenoviral vector containing a B cell epitope An adenoviral vector expressing a B cell epitope could increase the immunogenicity of a malaria vaccine. In a mouse model of malaria, immunization with an adenoviral vector containing a B cell epitope of Plasmodium yoelii circumsporozoite (CS) protein increased antibody and T cell responses and reduced parasite burden in the liver and
more » ... d compared with the same vector lacking the B cell epitope. Next steps include identifying the single or combination of malaria B cell epitopes that produce the most immunogenicity. Ad35-CS, a recombinant malaria vaccine with a vector based on adenovirus serotype 35 from Crucell N.V., is in Phase I testing for malaria.
doi:10.1038/scibx.2010.1107 fatcat:7zaqt4gzd5eotesyz62qrqvkry